SNIPR announces Publication of Final Positive Phase 1 Results for SNIPR001 in The Lancet Microbe

Scientific PublicationsPress Releases
Written By Christian Mygind

First-ever randomized, placebo-controlled Phase 1 trial - published in The Lancet Microbe - supports SNIPR001’s safety, tolerability, and restriction to the gastrointestinal tract in healthy participants

Press release

Research paper

Christian Mygind
Previous

Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
Next

SNIPR participates at 10th AMR Conference BEAM alliance 3-4 March 2026